News
ENDPQ
0.0010
+66.67%
0.0004
Weekly Report: what happened at ENDPQ last week (0219-0223)?
Weekly Report · 1d ago
Weekly Report: what happened at ENDPQ last week (0212-0216)?
Weekly Report · 02/19 09:42
Weekly Report: what happened at ENDPQ last week (0205-0209)?
Weekly Report · 02/12 09:39
Weekly Report: what happened at ENDPQ last week (0129-0202)?
Weekly Report · 02/05 09:42
Weekly Report: what happened at ENDPQ last week (0122-0126)?
Weekly Report · 01/29 09:39
Weekly Report: what happened at ENDPQ last week (0115-0119)?
Weekly Report · 01/22 09:40
Weekly Report: what happened at ENDPQ last week (0108-0112)?
Weekly Report · 01/15 09:39
Bankrupt Generic Drugmaker Endo Secures Court Approval for $600M Opioid Epidemic Compensation Plan
Endo International has gained approval to initiate the solicitation of votes for its restructuring plan. The company's restructuring plan outlines a $600 million trust to compensate creditors. The plan links opioid addiction to the company's painkiller Opana ER. A group of states, tribes, and private institutions is endorsing Endo's plan.
Benzinga · 01/11 19:09
Weekly Report: what happened at ENDPQ last week (0101-0105)?
Weekly Report · 01/08 09:40
Weekly Report: what happened at ENDPQ last week (1225-1229)?
Weekly Report · 01/01 09:38
Weekly Report: what happened at ENDPQ last week (1218-1222)?
Weekly Report · 12/25/2023 09:42
Endo files reorganization plan in effort to emerge from Chapter 11
Healthcare Endo files reorganization plan in effort to emerge from Chapter 11. The plan calls for a purchase of nearly all of Endo's assets and employment offers to all of the company's active workers. The pharma also includes a settlement in principle with the U.S. Justice Department.
Seeking Alpha · 12/19/2023 19:05
Weekly Report: what happened at ENDPQ last week (1211-1215)?
Weekly Report · 12/18/2023 09:44
AbbVie, Amgen among firms targeted for latest Medicare inflation penalties
AbbVie, Amgen among firms targeted for latest Medicare inflation penalties. Biden administration named 48 Medicare Part B drugs that could be subject to inflation penalties for Q1 2024. The initiative aims to cut out-of-pocket expenses for Medicare members and discourage drugmakers from raising prices faster than inflation. The penalized drugmakers will be required to pay the difference as a rebate.
Seeking Alpha · 12/14/2023 17:30
Weekly Report: what happened at ENDPQ last week (1204-1208)?
Weekly Report · 12/11/2023 09:42
Weekly Report: what happened at ENDPQ last week (1127-1201)?
Weekly Report · 12/04/2023 09:42
Weekly Report: what happened at ENDPQ last week (1120-1124)?
Weekly Report · 11/27/2023 09:40
Generic Drugmaker Endo's Bankruptcy: Lenders Suggest $465M Payment To Settle Dispute With Federal Entities: Report
Endo international's lenders have proposed a deal to settle with u.s. Government agencies in disagreement with the pharmaceutical company's restructuring strategy. Endo's first-lien debtholders propose to provide $365 million to the objecting agencies over a decade. The proposal suggests allocating up to $465 million to these agencies.
Benzinga · 11/22/2023 11:56
Endo Creditors Offer U.S. Government $465 Million to Push Sale Forward
Endo's first-lien debtholders say the government agencies would receive $365 million over 10 years. The justice department objected to endo's restructuring plan to hand control to creditors. Endo filed for bankruptcy in august 2022 to address mass opioid lawsuits.
The Wall Street Journal · 11/22/2023 03:32
Weekly Report: what happened at ENDPQ last week (1113-1117)?
Weekly Report · 11/20/2023 09:40
More
Webull provides a variety of real-time ENDPQ stock news. You can receive the latest news about Endo Intl Plc through multiple platforms. This information may help you make smarter investment decisions.
About ENDPQ
Endo International plc is a specialty pharmaceutical company. The Company operates through four business segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. Its Branded Pharmaceuticals segment includes a variety of branded products in the areas of urology, orthopedics, endocrinology, medical aesthetics and bariatrics, among others. Its products include XIAFLEX, SUPPRELIN LA, NASCOBAL Nasal Spray, AVEED, QWO, PERCOCET, TESTOPEL, EDEX and LIDODERM, among others. Its Sterile Injectables segment consists of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection. The Company's Generic Pharmaceuticals segment consists of a product portfolio, including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic and sprays.